Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05005975 · ClinicalTrials.gov registry record · Phase 3
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
A Phase 3 study of EPP and XLP, sponsored by Tanabe Pharma America.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 301
- Enrollment target
- 20
- Study locations
NCT05005975 is a Phase 3 study of EPP and XLP that is actively recruiting participants, run by Tanabe Pharma America. The registered enrollment target is 301 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT05005975, a Phase 3 study of EPP and XLP, is actively recruiting participants, sponsored by Tanabe Pharma America.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 301 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the long-term safety and tolerability of oral dersimelagon.
Interventions
- DRUG MT-7117
Study Locations (20)
California
- Marvel Clinical Research, LLC - Huntington Beach
- University of California at San Francisco - CSF Porphyria Center - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
- MetroBoston Clinical Partners, LLC - Brighton
Ohio
- Cleveland Clinic - Taussig Cancer Institute - Cleveland
- Remington-Davis Clinical Research - Columbus
Pennsylvania
- Thomas Jefferson University - Philadelphia
- Einstein Medical Center, Philadelphia - Philadelphia
Florida
- University Of Miami School Of Medicine, Center For Liver Diseases - Miami
Michigan
- Henry Ford Health System - Detroit
Missouri
- Kansas City Research Institute - Kansas City
New York
- Icahn School of Medicine at Mount Sinai (ISSMS)-The Mount Sinai Hospital (MSH) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2021-08-10 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05005975
The ClinicalTrials.gov registry entry for NCT05005975 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tanabe Pharma America, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with EPP appearing as the primary indexed condition, and to 1 intervention - of which MT-7117 is the first listed.
NCT05005975 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT05005975 about?
NCT05005975 is a clinical study titled "Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)". To evaluate the long-term safety and tolerability of oral dersimelagon.
What is the current status of trial NCT05005975?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 301 participants. The study started on 2021-08-10. Estimated completion is 2027-12.
What conditions does trial NCT05005975 study?
This clinical trial studies the following conditions: EPP, XLP.
What interventions are being tested in trial NCT05005975?
The interventions under investigation include: MT-7117 (DRUG).
Who is sponsoring clinical trial NCT05005975?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05005975 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.